The search for an oral vasodilator effective in relieving symptoms in patients with congestive heart failure has led several investigatorsl-3 to evaluate prazosin. This quinazoline derivative produces alpha-adrenergic blockade, dilating both arteries and veins and providing a balanced reduction in preload and afterload.' 4 After initial promising reports in acute and chronic congestive heart failure' 2 several investigators have reported tachyphlaxis during acute studies using continuous haemodynamic monitoring.5 6 The relevance of this acute phenomenon to chronic ambulatory treatment is uncertain, since other investigators have reported sustained benefit during chronic ambulatory treatment.2 7 8 Drug tolerance during chronic prazosin treatment has been described less frequently." 10 Long-term controlled studies with a large study population will eventually *Supported in part by the Herman C Krannert Fund; and by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health.
Received for publication 27 May 1980 be needed to resolve these conflicting results. In most reported chronic studies the patients have been evaluated by non-invasive means. The present study was designed to test the effects of prazosin during acute and chronic treatment for congestive heart failure over a 10-week period with sequential invasive haemodynamic measurements.
Subjects and methods
Eleven patients were initially evaluated and nine completed the 10-week study. Their clinical features are listed in Table 1 . There were seven men and four women aged 55 to 77 (mean 61 years). All patients had chronic congestive heart failure (mean duration 5-3 years) . Each patient entered the study after a period in hospital for decompensated congestive heart failure (NYHA class III or IV) while receiving digitalis and diuretics. The The study was divided into three phases. An initial inpatient pretreatment evaluation and titration with prazosin (phase I); an outpatient follow-up period lasting nine weeks (phase II); and a readmission for a final evaluation (phase III).
Phase I After informed consent the patients had right heart catheterisation and then entered into the study if their left ventricular filling pressure exceeded 15 mmHg and the cardiac index was less than 2-5 1/min per M2.
The patients were titrated slowly with increasing doses of prazosin on an eight hour schedule until maximum benefit was felt to be achieved as determined by daily assessment of their symptoms and signs of congestive heart failure. This took an average dose of 5-6 ±2-2 mg every eight hours, and an average of six days. Prazosin was then withheld Phase I   III  I  III  I  III  I  III  I  III P C PZ C PZ P C PZ C PZ P C PZ C PZ P C PZ C PZ P C PZ C PZ The haemodynamic data are presented in Table 2 and Fig. 1 to 3 . Table 2 shows the pretreatment, post-titration control measurements after washout and peak response to prazosin during the initial period in hospital (phase I), and the post-washout control measurements and peak response to prazosin after 10 weeks of treatment (phase III (Fig. 2, Table 2 ). One patient failed to respond to prazosin; but the group as a whole showed a significant reduction in mean arterial pressure (p < 0 02), mean pulmonary artery pressure (p < 0.05), pulmonary artery wedge (p < 0.02), stroke volume index (p < 0-05), and systemic vascular resistance (p <0-01) when compared with the washout control measurements. The reduction in mean arterial pressure and pulmonary artery wedge pressure was sustained and remained significant during the four hours it was measured (Fig. 2, panel b) . The cardiac index, however, failed to increase. The reason for this becomes clear when one compared the ventricular function curves in Fig. 2 . During phase I, the control pulmonary artery wedge pressure was raised in all patients and after administration of prazosin all but one patient increased their cardiac index significantly as they We were able to show a significant haemodynamic improvement in 10 out of 11 patients after initial administration and titration of prazosin treatment and this improvement was still evident in eight of nine patients who completed the 10 weeks of ambulatory prazosin treatment. Several investigators have recently reported pharmacodynamic tachyphylaxis to prazosin during short-term administration under haemodynamic monitoring,5 6 but others have failed to confirm this observation.11 This phenomenon is poorly understood and it may be manifest at rest but not during exercise. '2 Our procedure for invasive haemodynamic assessment followed an 18 to 24 hour washout period. It is possible that the mechanisms causing tachyphylaxis reversed during this interval and responsiveness to prazosin was restored when readministered. All but one of our patients, however, reported clinical improvement at the start of the washout and haemodynamic studies. In three patients the improvement could have been related in part to the increase in diuretic treatment; this would not explain, however, the improvement in the other seven. Furthermore, we noted that after the final washout period there was a significant reduction in the control heart rate, pulmonary artery wedge pressure, right atrial pressure, stroke volume index, stroke work index, and systemic vascular resistance when compared with the pretreatment baseline. These results suggest a persistent effect of prazosin treatment after the drug had cleared from the plasma. Prazosin as well as hydralazine and minoxidil have been shown to remain in the blood vessel walls for longer periods.'3 An alteration of the many feedback loops or endogenous chemicals, hormones, and neurotransmitters involved in the homeostasis of congestive heart failure during chronic prazosin treatment may be an additional or alternative explanation.
During the final administration of prazosin one patient failed to respond and three others showed a blunting of the cardiac index response. Blunting of haemodynamic responses has been previously reported during chronic prazosin treatment'0 11 and less frequently with hydralazine."4 Significant haemodynamic improvement was shown, however, in most of our patients after 10 weeks. If one were to accept the studies that show acute haemodynamic tachyphylaxis as the predictors of chronic effectiveness of prazosin treatment, one would not expect to see the beneficial responses observed in our patients or those patients reported in other long term studies.7 8 We, therefore, must question the clinical relevance of acute haemodynamic tachyphylaxis in predicting the effectiveness of chronic prazosin treatment for congestive heart failure. It has been shown that the acute haemodynamic changes produced by reserpine and propranolol during treatment for hypertension may be quite different from those that occur during chronic administration.'3 For example, the cardiac output decreases during the initiation of treatment with reserpine but returns to control levels during chronic treatment. Propranolol increases the systemicvascular resistance acutely but lowers it during chronic treatment. This suggests that long term effects of vasodilator therapy cannot always be predicted with acute drug testing and are best examined with long term studies.
Conclusions
Our study indicates that in spite of the development of tolerance, significant haemodynamic benefits from prazosin can be shown in many patients for several weeks. Our results can only be considered preliminary as the number of patients was small, the study uncontrolled, and the follow-up extended to only 10 weeks. The differences in patient population and study design and the small number reported by others, usually in uncontrolled studies, make it difficult to reach definitive conclusions. We believe that the haemodynamic effectiveness of prazosin in congestive heart failure should be examined in a larger study population with double blind controlled studies to assess conclusively its value in the long term treatment of chronic congestive heart failure. 
